Concepedia

Author

Jessica A. Pollard

University of Southern CaliforniaORCID

Also Known As

J Pollard, J. A. Pollard, J. Pollard, Jessica A Pollard, Jessica A. Pollard, Jessica Anne Pollard, Jessica Pollard

177

Publications

2.8K

Citations

28

H-Index

33

Concepts

All Affiliations

University of Southern CaliforniaFred Hutch Cancer CenterChildren's Hospital of PhiladelphiaSt. Jude Children's Research HospitalChildren's Oncology Group
JA

About

Jessica A. Pollard is an author at University of Southern California specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

94

2

Health Sciences

3

3

47

3

Blood Transplantation

1

1

15

4

Cell Biology

1

1

18

5

Cellular Physiology

1

1

18

Jessica A. Pollard

×

49

Publications

2.5K

Citations

27

H-Index

YearCitations

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing,

Blood

2009

216

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

Jessica A. Pollard, Todd A. Alonzo, Robert B. Gerbing,

Blood

2010

181

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

Richard Aplenc, Soheil Meshinchi, Lillian Sung,

Haematologica

2020

166

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531

Jatinder K. Lamba, Lata Chauhan, Miyoung Shin,

Journal of Clinical Oncology

2017

146

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531

Jessica A. Pollard, Michael R. Loken, Robert B. Gerbing,

Journal of Clinical Oncology

2016

137

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

Jessica A. Pollard, Todd A. Alonzo, Michael R. Loken,

Blood

2012

110

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i> -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531

Jessica A. Pollard, Erin Guest, Todd A. Alonzo,

Journal of Clinical Oncology

2021

105

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Phoenix A. Ho, Rong Zeng, Todd A. Alonzo,

Blood

2010

93

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia &amp; Lymphoma (TACL) Study

Todd M. Cooper, Jeannette Cassar, Elena Eckroth,

Clinical Cancer Research

2016

72

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)

Todd M. Cooper, Edward Allan R. Sison, Sharyn D. Baker,

Pediatric Blood & Cancer

2017

71

Page 1